Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending January 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMR), or connected persons, specifically regarding the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in the American Depositary Shares (ADSs) held by Mr. D E Troy, a Person Discharging Managerial Responsibility. This increase resulted from the re-investment of dividends paid to shareholders on January 8, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of a specific share transaction executed at a price of $43.19 per ADS.
Key Facts for Investors to Verify
- Transaction Date: Notification received on January 16, 2015; filing date January 19, 2015.
- Individual Involved: Mr. D E Troy (PDMR).
- Transaction Type: Increase in ADS holdings via dividend re-investment.
- Transaction Price: $43.19 per ADS.
- ADS Quantity: 384.909 ADSs.
- Dividend Date: January 8, 2015.